



**CHILDREN'S & WOMEN'S HEALTH
CENTRE OF BRITISH COLUMBIA**

AN AGENCY OF THE PROVINCIAL HEALTH SERVICES AUTHORITY

DIVISION OF PEDIATRIC

HEMATOLOGY / ONCOLOGY / BONE MARROW TRANSPLANT

**SUMMARY FOR FOLLOW UP CLINIC
WORK SHEET**

Re:

DOB:

BCCH#:

BCCA#:

PHN:

Diagnosis:

Date of Diagnosis:

Age at Diagnosis:

Protocol:

Start of Treatment:

End of Treatment:

Total Anthracycline dose:

Radiation (Dose, Site):

Relapse (Yes, No):

Past Medical History:

Family History:

Initial History & Examination:

Initial Investigations:

Overall Treatment Course

(Describe overall course of treatment given. If relevant describe reasons for decisions eg Surgery vs radiation, choice of chemo protocol)
If patient relapsed, add a heading for relapse and describe course of relapse treatment)

Chemotherapy:

List protocols used and all drugs received

Cumulative total:

- Anthracyclines (if received more than one type of anthracycline **calculate anthracycline equivalency**)- see appendix
- Alkylating drugs (cyclo, ifos, procarbazine, chlorambucil, BCNU, CCNU, Melphalan, thiotepa, Busulfan, Nit mustard) **Calculate cyclophosphamide equivalent dose**- see appendix
- Cisplatin, carboplatin
- Bleomycin

Radiation:

Date, dose and site

Surgical Procedures:

Date and procedure

Problems During Treatment:

List and describe. Resolved Y/N

Problems Occurring Since Completion of Treatment

List and describe. Resolved Y/N

Current Status (date):

Anticipated / Potential Future Problems:

Cardiac

Growth / Development

Endocrine:

Fertility

Second malignancy

Pulmonary

Bones / joints

Neurologic

Renal

Psychosocial

Education/vocation

Vision

Hearing

Dental

Genetic risk

Recommended Follow Up:

Physical Exam (frequency, where)

Labs (type, frequency, where)

Imaging

Echos, PFTs

Anthracycline Cardiotoxicity Equivalent doses:

Agent	Correction factor
Doxorubicin	1.0
Daunorubicin	1.0
Epirubicin	0.67
Mitoxantrone	4.0
Idarubicin	5.0

Chow, E et al, JCO, 2015 Feb 10;33(5);394-402

Barnard, DR in Altman AJ (ed) Supportive care of children with cancer, 2004, 122-127

Cardiac Surveillance Guidelines (BC)

Anthracycline Dose*	Radiation Dose**	Recommended Frequency of Echo
None	< 15 Gy or none	No Screening
	15 - < 35 Gy	Every 5 years
	35 Gy	Every 2 years
< 250 mg/m ²	< 15 Gy or none	Every 5 years
	15 Gy	Every 2 years
250 mg/m ²	Any or none	Every 2 years

*Based on total doses of doxorubicin or the equivalent doses of other anthracyclines

**Based on radiation dose with potential impact to heart (radiation to chest, abdomen, spine [thoracic, whole], total body [TBI])

COG LTFU Guidelines version 5.0 (Oct 2018)

Dose equivalents of alkylators Green DM. Pediatr Blood Cancer 2014;61:53-67	
• Agent dose mg/m ²	Correction factor
• Cyclophosphamide	1.0
• Ifosphamide	0.244
• Procarbazine	0.857
• Chlorambucil	14.286
• BCNU	15
• CCNU	16
• Melphelan	40
• Thiotepa	50
• Nitrogen Mustard	100
• Busulphan	8.823

Risk of alkylator Infertility		
• CTX equivalent mg/m ²	Male	Female
• <4000	unlikely	unlikely
• 4000-8000	40%	30%
• 8000-20000	60%	50%
• >20000	90%	80%
• These figures are very approximate with confidence intervals varying up to +/- 15%		
• Green DM Pediatr Blood Cancer 2014;61:53-67 (female data)		
• Green DM J Clin Oncol 2010;28:332-9 (male data)		